Japanese Encephalitis (JEV) Infection Drug Development Pipeline Study, H2 2018
Japanese Encephalitis (JEV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Japanese Encephalitis (JEV) Infection pipeline products.
DISEASE OVERVIEW
Japanese encephalitis virus or JAVEX is a viral infection caused by encephalitis virus. The disease is a rare disease but morbidity rate is around 30% and permanent neurologic sequelae occur in 30% to 50% cases. In Asia alone, 68,000 cases are diagnosed with Japanese Encephalitis infections every year according to WHO. Fever, seizures, head-ache, spastic paralysis are main symptoms of the disease. Around one third of patients who survive can witness neurological and speech related issues.
Primarily Asian countries and Oceania countries including Australia, Bangladesh, Myanmar, Cambodia, China, India, Indonesia, Japan, Malaysia, Nepal, Koreas, Pakistan, PNG, Philippines, Singapore, Sri Lanka, Taiwan, Thailand, Vietnam and European countries including Russia, Spain are mainly considered as risk prone areas.
Ennaid Therapeutics LLC, Kineta Inc and Panacea Biotec Ltd are developing vaccines and anti-viral peptides for treatment/ prevention of Japanese encephalitis infections.
REPORT DESCRIPTION
The Japanese Encephalitis (JEV) Infection pipeline guide presents complete overview of drugs currently being developed for Japanese Encephalitis (JEV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Japanese Encephalitis (JEV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Japanese Encephalitis (JEV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Japanese Encephalitis (JEV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Japanese Encephalitis (JEV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Japanese Encephalitis (JEV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Japanese Encephalitis (JEV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Japanese encephalitis virus or JAVEX is a viral infection caused by encephalitis virus. The disease is a rare disease but morbidity rate is around 30% and permanent neurologic sequelae occur in 30% to 50% cases. In Asia alone, 68,000 cases are diagnosed with Japanese Encephalitis infections every year according to WHO. Fever, seizures, head-ache, spastic paralysis are main symptoms of the disease. Around one third of patients who survive can witness neurological and speech related issues.
Primarily Asian countries and Oceania countries including Australia, Bangladesh, Myanmar, Cambodia, China, India, Indonesia, Japan, Malaysia, Nepal, Koreas, Pakistan, PNG, Philippines, Singapore, Sri Lanka, Taiwan, Thailand, Vietnam and European countries including Russia, Spain are mainly considered as risk prone areas.
Ennaid Therapeutics LLC, Kineta Inc and Panacea Biotec Ltd are developing vaccines and anti-viral peptides for treatment/ prevention of Japanese encephalitis infections.
REPORT DESCRIPTION
The Japanese Encephalitis (JEV) Infection pipeline guide presents complete overview of drugs currently being developed for Japanese Encephalitis (JEV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Japanese Encephalitis (JEV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Japanese Encephalitis (JEV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Japanese Encephalitis (JEV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Japanese Encephalitis (JEV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Japanese Encephalitis (JEV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Japanese Encephalitis (JEV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE REPORT INCLUDES
- Panorama of Japanese Encephalitis (JEV) Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Japanese Encephalitis (JEV) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Japanese Encephalitis (JEV) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Japanese Encephalitis (JEV) Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Japanese Encephalitis (JEV) Infection pipeline therapeutics
- Get clear understanding of the entire Japanese Encephalitis (JEV) Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Japanese Encephalitis (JEV) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Japanese Encephalitis (JEV) Infection Pipeline include-
Number of Companies with Japanese Encephalitis (JEV) Infection projects in pre-clinical Development-
Number of Companies with Japanese Encephalitis (JEV) Infection projects in Clinical Development-
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Americas
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Europe
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Asia Pacific
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Japanese Encephalitis (JEV) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Japanese Encephalitis (JEV) Infection Pipeline Agents in Clinical Development stage
Japanese Encephalitis (JEV) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Japanese Encephalitis (JEV) Infection Pipeline agents
II. INSIGHTS INTO JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE
1. Disease Overview
Introduction to Japanese Encephalitis (JEV) Infection
Symptoms and Causes of Japanese Encephalitis (JEV) Infection
Treatment or Prevention Options for Japanese Encephalitis (JEV) Infection
Other Details
2. Phase wise Pipeline Compounds
Japanese Encephalitis (JEV) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 1 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 2 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 3 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Japanese Encephalitis (JEV) Infection Pipeline Compounds
4. Japanese Encephalitis (JEV) Infection Pipeline by Mechanism of Action
III. JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE COMPOUND DETAILS
anti-viral peptide for Japanese Encephalitis
Japanese encephalitis vaccine
Vero cell based vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE COMPANY BRIEFS
Ennaid Therapeutics LLC
Kineta Inc
Panacea Biotec Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Japanese Encephalitis (JEV) Infection Pipeline include-
Number of Companies with Japanese Encephalitis (JEV) Infection projects in pre-clinical Development-
Number of Companies with Japanese Encephalitis (JEV) Infection projects in Clinical Development-
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Americas
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Europe
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Asia Pacific
Japanese Encephalitis (JEV) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Japanese Encephalitis (JEV) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Japanese Encephalitis (JEV) Infection Pipeline Agents in Clinical Development stage
Japanese Encephalitis (JEV) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Japanese Encephalitis (JEV) Infection Pipeline agents
II. INSIGHTS INTO JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE
1. Disease Overview
Introduction to Japanese Encephalitis (JEV) Infection
Symptoms and Causes of Japanese Encephalitis (JEV) Infection
Treatment or Prevention Options for Japanese Encephalitis (JEV) Infection
Other Details
2. Phase wise Pipeline Compounds
Japanese Encephalitis (JEV) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 1 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 2 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Phase 3 stage Drugs
Japanese Encephalitis (JEV) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Japanese Encephalitis (JEV) Infection Pipeline Compounds
4. Japanese Encephalitis (JEV) Infection Pipeline by Mechanism of Action
III. JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE COMPOUND DETAILS
anti-viral peptide for Japanese Encephalitis
Japanese encephalitis vaccine
Vero cell based vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE COMPANY BRIEFS
Ennaid Therapeutics LLC
Kineta Inc
Panacea Biotec Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL JAPANESE ENCEPHALITIS (JEV) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
